secwatch.observer — SEC 8-K summary
======================================

Issuer:     CHAMPIONS ONCOLOGY, INC. (CSBR)
CIK:        0000771856
Form:       8-K
Filed at:   2024-07-18T23:59:59+00:00
Accession:  0001628280-24-032227
Event type: earnings
Sentiment:  negative
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Champions Oncology reports FY2024 revenue down 7% to $50.2M; Q4 adjusted EBITDA turns positive $884K
--------------------------------------------------------------------------------

- Q4 revenue $14.0M (+7% YoY); Q4 adjusted EBITDA income $884K vs loss $922K prior year.
- FY2024 revenue $50.2M (-7% YoY); FY adjusted EBITDA loss $3.9M vs loss $1.3M prior year.
- Q4 gross margin 48% (pharmacology services 49%); FY gross margin 41% vs 45% prior year.
- Cash $2.6M, no debt; stock repurchase program paused; Corellia AI unit seeking external capital.
- Q4 operating loss $190K narrowed from $2.5M prior year; cost-cutting measures improving bottom line.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/771856/000162828024032227/0001628280-24-032227-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/771856/000162828024032227/csbr-20240718.htm
  HTML page:      https://secwatch.observer/filing/0001628280-24-032227

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer